SMAD2 and hepatocellular carcinoma: Subsets of gastrointestinal cancers, including HCC, are also known to inactivate TGFβ‐RI and downstream signaling components, such as SMAD2 and SMAD4, through genomic, epigenomic, and transcriptomic alterations.26